GALTNasdaq United States
Market cap
$347.931 M
$3.45 +7.14%
Close of 7 Aug 2026
Revenue
—
Not reported
Earnings
-$30.8M
Loss-making
Shares outstanding
65,827,448
Latest filing cover page
P/E ratio
—
Cap ÷ net income
Where these numbers come from
Share counts and financials for Galectin Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.